Figure 3From: Treatment of one case of cerebral palsy combined with posterior visual pathway injury using autologous bone marrow mesenchymal stem cellsBMSC surface marker detection: CD44 and CD29 positive rates were greater than 95%, the CD106 positive rate was greater than 80%, and the CD34, CD45, CD14, and HLA-DR expression rates were less than 5%.Back to article page